Diffusion tensor invasive phenotypes can predict progression-free survival in glioblastomas. (August 2013)

• Record Type: Journal Article
• Authors: Mohsen, L. A.; Shi, V.; Jena, R.; Gillard, J. H.; Price, S. J.
• Is Part Of: British journal of neurosurgery. Volume 27:Number 4(2013:Aug.)
• Page Start: 436
• Page End: 441
• Publication Date: 2013-08
• Subjects: DTI -- glioblastoma -- patterns of invasion -- PFS -- progression; Nervous system -- Surgery -- Periodicals; 617.48
• DOI: 10.3109/02688697.2013.771136
• Languages: English
• ISSNs: 0268-8697

Abstract

Abstract: Introduction . Glioblastomas multiformes (GBM) remain incurable in most cases. Their invasion into normal brain makes current therapies ineffective. Post-mortem studies suggest about a 25% of GBMs invade less than 1 cm from the tumour bulk and 20% invade more than 3 cm. Aim of study. The study aims to use DTI to assess tumour extension and determine how previously reported patterns relate to the progression-free survival (PFS). Materials and methods. Twenty-five patients with GBM treated according to the EORTC/NCIC protocol were retrospectively analysed. Patients were imaged post-operatively at 1.5 T. The sequences were composed of standard anatomical and a standard DTI sequence. As described earlier p and q maps were constructed. For each of the p and q maps, regions of interest were drawn around the visible abnormality. Patients were assigned a diffuse, localised or minimally invasive pattern. Progression was defined according to the RANO criteria 4 and PFS determined in days. Kaplan–Meier plots of survival for the three groups were plotted as were the proportion of patients who had not progressed at 24 months. Results . The median PFS for the diffuse group was 278 days, for the localised group 605 days and 820 days for the minimally invasive group. Three-fourth of the minimally invasive group were progression-free at 24 months (LOG RANK 9.25; p = 0.010). Conclusion . It is possible to identify three invasive phenotypes in GBMs using Diffusion tensor imaging, and these three phenotypes have different progression free survival. A minimal phenotype (20% of patients) predicts a greater delay to progression.